Product Description
Mechanisms of Action: CaSR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Kyowa Hakko Kirin
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hyperparathyroidism, Primary|Hypercalcemia|Hyperparathyroidism, Secondary
Phase 2: Hyperparathyroidism, Secondary
Phase 1: Hyperparathyroidism, Secondary|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03822507 | P3 |
Completed |
Hyperparathyroidism, Secondary |
2021-09-23 |
55% |
| NCT04206657 | P1 |
Completed |
Healthy Volunteers |
2021-06-17 |
28% |
| JapicCTI-173684 | P3 |
Unknown |
Hyperparathyroidism, Primary|Hypercalcemia |
2019-10-01 |
|
| NCT03280264 | P3 |
Completed |
Hypercalcemia|Hyperparathyroidism, Primary |
2019-04-09 |